Cavidi’s technology offers unique features; the assay can detect all subtypes of HIV where the other diagnostics technologies only detect the major subgroups.
The Ziva™ system is a fully automated benchtop product with higher throughput and less hands-on time than other solutions in the mid-market segment, making it uniquely tailored for the needs of these labs.
In February 2020, Impilo reached an agreement with the majority shareholder of Cavidi, resulting in a sale of all instruments by Impilo against a proceeds split in the future. At the time of the agreement, Impilo had a 34% ownership in the company.
Key events under Impilo ownership 2018-2020:
- Improved governance model and financial and operational reporting
- Strengthened leadership with new CEO, CFO and R&D manager, as well as recruitment of key development project resource
- Strengthened project management setup and significant progress in the Ziva development project
- Progress in distributor search in preparation for commercialization
